Development and biological evaluation of vesicles containing bile salt of telmisartan for the treatment of diabetic nephropathy. (31st October 2018)

• Record Type: Journal Article
• Authors: Ahad, Abdul; Raish, Mohammad; Ahmad, Ajaz; Al-Jenoobi, Fahad I.; Al-Mohizea, Abdullah M.
• Is Part Of: Artificial cells, nanomedicine, and biotechnology. Volume 46(2018)Supplement 1
• Page Start: 532
• Page End: 539
• Publication Date: 2018-10-31
• Subjects: Diabetic nephropathy -- renoprotective effects -- streptozotocin -- telmisartan -- vesicles containing bile salt; Artificial cells -- Periodicals; Nanotechnology -- Periodicals; Blood substitutes -- Periodicals; Tissue engineering -- Periodicals; Molecules -- Periodicals; Biotechnology -- Periodicals; 615.39
• DOI: 10.1080/21691401.2018.1430700
• Languages: English
• ISSNs: 2169-1401

Abstract

Abstract: The aim of present study was to develop and evaluate vesicles containing bile salt formulation of telmisartan for the treatment of diabetic nephropathy. Different vesicles containing bile salt formulations were developed by varying ratios of soybean phosphatidylcholine and sodium deoxycholate. Prepared formulations were characterized for their size, polydispersity index, zeta potential, morphology and entrapment efficiency. Further, the renoprotective outcome of optimized formulation was studied in streptozotocin-induced diabetic nephropathy rat model. Results of the present study demonstrated that the average vesicles size, polydispersity index, zeta potential and entrapment efficiency were found to be in the range of 64.98 ± 1.40 to 167.60 ± 6.46 nm, 0.02 ± 0.04 to 0.31 ± 0.01, −24.30 ± 1.39 to −42.60 ± 6.67 mV and 29.68 ± 1.08% to 77.21 ± 0.52%, respectively. Further, the best chosen formulation F4 presented vesicles size, polydispersity index, zeta potential and entrapment efficiency of 64.98 ± 1.40 nm, 0.24 ± 0.02, −35.40 ± 1.48 mV and 77.21 ± 0.52%, respectively. In addition, formulation F4 improved the biological indices in streptozotocin-induced diabetic nephropathy in rats. It was concluded that prepared formulation exerts a valuable results on diabetic nephropathy and it may be a potential pharmaceutical dosage form for the treatment of diabetic nephropathy.